Free Newsletter
Study: Antidepressant warnings work
Here are your tax dollars at work: FDA warnings about the suicide risks associated with antidepressants curtailed use among youngsters, just as they were designed to do, according to a new study. And though growth in that drug class has slowed, the warnings didn't scare patients into a mass stampede away from them as critics had feared.
Researchers studied prescription rates during the period just before the first warning, issued for Paxil only, appeared in 2003; during the next 16 months, before the "black box" warning was added to all SSRIs; and for the 15 months after the black boxes. Paxil scrips fell off by 44 percent after the 2003 warning, but use of the other antidepressants continued to rise, falling off only a bit after the wholesale warning in 2005. New patients continued to sign up for the drugs, too.
The upshot: Treatment changes were "modest" overall, and greatest among the very group targeted by the warnings, researchers said.
- read the abstract in Archives of General Psychiatry
- here's the report from the New York Times
- get more from MedPage Today
Related Articles:
FDA orders new warnings for antidepressants. Report
Antidepressants: Top 10 warnings and recalls of 2007. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





